The bacterial microbiota in inflammatory lung diseases

Clinical Immunology

Volumn 159, Issue 2, 2015, Pages 177-182

  Huffnagle, Gary B ^a   Dickson, Robert P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aerodigestive; Bacteria; Disease; Lung; Microaspiration; Microbiota

Indexed keywords

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL FLORA; BACTERIAL INFECTION; BACTERIAL SURVIVAL; BACTERIUM CULTURE; CHRONIC LUNG DISEASE; CYTOLOGY; DISEASE EXACERBATION; HUMAN; INNATE IMMUNITY; MICROBIOME; MICROENVIRONMENT; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS; RESPIRATORY SYSTEM; SURVIVAL; TURNOVER TIME; ACID ASPIRATION; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; DISEASE COURSE; IMMUNOLOGY; LUNG; LUNG DISEASE; MICROBIOLOGY; MICROFLORA; MOUSE;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; LUNG; LUNG DISEASES; MICE; MICROBIOTA; RESPIRATORY ASPIRATION;

EID: 84952628142     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.05.022     Document Type: Article

References (96)

1. Cotran R.S., Kumar V., Collins T., Robbins S.L. Robbins Pathologic Basis of Disease 1999, Saunders, Philadelphia. 6th ed.
2. Dickson R.P., Erb-Downward J.R., Huffnagle G.B. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 2013, 7:245-257.
3. Dickson R.P., Erb-Downward J.R., Huffnagle G.B. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Res. Med. 2014, 2:238-246.
4. Hilty M., Burke C., Pedro H., Cardenas P., Bush A., Bossley C., Davies J., Ervine A., Poulter L., Pachter L., Moffatt M.F., Cookson W.O. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5:e8578.
5. Huang Y.J., Lynch S.V. The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert Rev. Respir. Med. 2011, 5:809-821.
6. Charlson E.S., Bittinger K., Chen J., Diamond J.M., Li H., Collman R.G., Bushman F.D. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS One 2012, 7:e42786.
7. Charlson E.S., Bittinger K., Haas A.R., Fitzgerald A.S., Frank I., Yadav A., Bushman F.D., Collman R.G. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 2011, 184:957-963.
8. Erb-Downward J.R., Thompson D.L., Han M.K., Freeman C.M., McCloskey L., Schmidt L.A., Young V.B., Toews G.B., Curtis J.L., Sundaram B., Martinez F.J., Huffnagle G.B. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011, 6:e16384.
9. Huang Y.J., Nelson C.E., Brodie E.L., Desantis T.Z., Baek M.S., Liu J., Woyke T., Allgaier M., Bristow J., Wiener-Kronish J.P., Sutherland E.R., King T.S., Icitovic N., Martin R.J., Calhoun W.J., Castro M., Denlinger L.C., Dimango E., Kraft M., Peters S.P., Wasserman S.I., Wechsler M.E., Boushey H.A., Lynch S.V. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J. Allergy Clin. Immunol. 2011, 127:372-381. (e371-373).
10. Morris A., Beck J.M., Schloss P.D., Campbell T.B., Crothers K., Curtis J.L., Flores S.C., Fontenot A.P., Ghedin E., Huang L., Jablonski K., Kleerup E., Lynch S.V., Sodergren E., Twigg H., Young V.B., Bassis C.M., Venkataraman A., Schmidt T.M., Weinstock G.M. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care Med. 2013, 187:1067-1075.
11. Pragman A.A., Kim H.B., Reilly C.S., Wendt C., Isaacson R.E. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012, 7:e47305.
12. Sze M.A., Dimitriu P.A., Hayashi S., Elliott W.M., McDonough J.E., Gosselink J.V., Cooper J., Sin D.D., Mohn W.W., Hogg J.C. The lung tissue microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012, 185:1073-1080.
13. Gleeson K., Eggli D.F., Maxwell S.L. Quantitative aspiration during sleep in normal subjects. Chest 1997, 111:1266-1272.
14. Huxley E.J., Viroslav J., Gray W.R., Pierce A.K. Pharyngeal aspiration in normal adults and patients with depressed consciousness. Am. J. Med. 1978, 64:564-568.
15. Quinn L.H., Meyer O.O. The relationship of sinusitis and bronchiectasis. Arch. Otolaryngol. Head Neck Surg. 1929, 10:152.
16. Bassis C.M., Erb-Downward J.R., Dickson R.P., Freeman C.M., Schmidt T.M., Young V.B., Beck J.M., Curtis J.L., Huffnagle G.B. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 2015, 6:e00037.
17. Dickson R.P., Martinez F.J., Huffnagle G.B. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014, 384:691-702.
18. Helander H.F., Fandriks L. Surface area of the digestive tract - revisited. Scand. J. Gastroenterol. 2014, 49:681-689.
19. Hasleton P.S. The internal surface area of the adult human lung. J. Anat. 1972, 112:391-400.
20. MacArthur R.H., Wilson E.O. An equilibrium theory of insular zoogeography. Evolution 1963, 373-387.
21. Lighthart B. Mini-review of the concentration variations found in the alfresco atmospheric bacterial populations. Aerobiologia 2000, 16:7-16.
22. Bertolini V., Gandolfi I., Ambrosini R., Bestetti G., Innocente E., Rampazzo G., Franzetti A. Temporal variability and effect of environmental variables on airborne bacterial communities in an urban area of Northern Italy. Appl. Microbiol. Biotechnol. 2013, 97:6561-6570.
23. Bowers R.M., McLetchie S., Knight R., Fierer N. Spatial variability in airborne bacterial communities across land-use types and their relationship to the bacterial communities of potential source environments. ISME J. 2010, 5:601-612.
24. Bowers R.M., Sullivan A.P., Costello E.K., Collett J.L., Knight R., Fierer N. Sources of bacteria in outdoor air across cities in the midwestern United States. Appl. Environ. Microbiol. 2011, 77:6350-6356.
25. Fierer N., Liu Z., Rodriguez-Hernandez M., Knight R., Henn M., Hernandez M.T. Short-term temporal variability in airborne bacterial and fungal populations. Appl. Environ. Microbiol. 2008, 74:200-207.
26. Munyard P., Bush A. How much coughing is normal?. Arch. Dis. Child. 1996, 74:531-534.
27. Wu H., Kuzmenko A., Wan S., Schaffer L., Weiss A., Fisher J.H., Kim K.S., McCormack F.X. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J. Clin. Invest. 2003, 111:1589-1602.
28. Dickson R.P., Erb-Downward J.R., Prescott H.C., Martinez F.J., Curtis J.L., Lama V.N., Huffnagle G.B. Cell-associated bacteria in the human lung microbiome. Microbiome 2014, 2:28.
29. West J.B. Regional differences in the lung. Chest 1978, 74:426-437.
30. Ingenito E.P., Solway J., McFadden E.R., Pichurko B., Bowman H.F., Michaels D., Drazen J.M. Indirect assessment of mucosal surface temperatures in the airways: theory and tests. J. Appl. Physiol. 1987, 63:2075-2083.
31. Hatch T.F. Distribution and deposition of inhaled particles in respiratory tract. Bacteriol. Rev. 1961, 25:237-240.
32. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008, 359:2355-2365.
33. Segal L.N., Alekseyenko A.V., Clemente J.C., Kulkarni R., Wu B., Chen H., Berger K.I., Goldring R.M., Rom W.N., Blaser M.J., Weiden M.D. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 2013, 1:19.
34. Dickson R.P., Erb-Downward J.R., Freeman C.M., Walker N., Scales B.S., Beck J.M., Martinez F.J., Curtis J.L., Lama V.N., Huffnagle G.B. Changes in the lung microbiome following lung transplantation include the emergence of two distinct pseudomonas species with distinct clinical associations. PLoS One 2014, 9:e97214.
35. Charlson E.S., Chen J., Custers-Allen R., Bittinger K., Li H., Sinha R., Hwang J., Bushman F.D., Collman R.G. Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS One 2010, 5:e15216.
36. Huang Y.J., Kim E., Cox M.J., Brodie E.L., Brown R., Wiener-Kronish J.P., Lynch S.V. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 2010, 14:9-59.
37. Daniels T., Rogers G., Stressmann F., van der Gast C., Bruce K., Jones G., Connett G., Legg J., Carroll M. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J. Cyst. Fibros. 2012, 12(1):22-28.
38. Delhaes L., Monchy S., Frealle E., Hubans C., Salleron J., Leroy S., Prevotat A., Wallet F., Wallaert B., Dei-Cas E., Sime-Ngando T., Chabe M., Viscogliosi E. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community - implications for therapeutic management. PLoS One 2012, 7:e36313.
39. Fodor A.A., Klem E.R., Gilpin D.F., Elborn J.S., Boucher R.C., Tunney M.M., Wolfgang M.C. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012, 7:e45001.
40. Stressmann F.A., Rogers G.B., van der Gast C.J., Marsh P., Vermeer L.S., Carroll M.P., Hoffman L., Daniels T.W.V., Patel N., Forbes B. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 2012, 67:867-873.
41. Zhao J., Schloss P.D., Kalikin L.M., Carmody L.A., Foster B.K., Petrosino J.F., Cavalcoli J.D., VanDevanter D.R., Murray S., Li J.Z., Young V.B., LiPuma J.J. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5809-5814.
42. Coxson H.O., Hogg J.C., Mayo J.R., Behzad H., Whittall K.P., Schwartz D.A., Hartley P.G., Galvin J.R., Wilson J.S., Hunninghake G.W. Quantification of idiopathic pulmonary fibrosis using computed tomography and histology. Am. J. Respir. Crit. Care Med. 1997, 155:1649-1656.
43. Coxson H.O., Rogers R.M., Whittall K.P., D'Yachkova Y., Pare P.D., Sciurba F.C., Hogg J.C. A quantification of the lung surface area in emphysema using computed tomography. Am. J. Respir. Crit. Care Med. 1999, 159:851-856.
44. D'Ovidio F., Singer L.G., Hadjiliadis D., Pierre A., Waddell T.K., de Perrot M., Hutcheon M., Miller L., Darling G., Keshavjee S. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann. Thorac. Surg. 2005, 80:1254-1260.
45. Raghu G., Freudenberger T.D., Yang S., Curtis J.R., Spada C., Hayes J., Sillery J.K., Pope C.E., Pellegrini C.A. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006, 27:136-142.
46. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., Birrer P., Bellon G., Berger J., Weiss T., Botzenhart K., Yankaskas J.R., Randell S., Boucher R.C., Doring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002, 109:317-325.
47. Schmidt A., Belaaouaj A., Bissinger R., Koller G., Malleret L., D'Orazio C., Facchinelli M., Schulte-Hubbert B., Molinaro A., Holst O., Hammermann J., Schniederjans M., Meyer K.C., Damkiaer S., Piacentini G., Assael B., Bruce K., Haussler S., Lipuma J.J., Seelig J., Worlitzsch D., Doring G. Neutrophil elastase-mediated increase in airway temperature during inflammation. J. Cyst. Fibros. 2014, 13(6):623-631.
48. Roy M.G., Livraghi-Butrico A., Fletcher A.A., McElwee M.M., Evans S.E., Boerner R.M., Alexander S.N., Bellinghausen L.K., Song A.S., Petrova Y.M., Tuvim M.J., Adachi R., Romo I., Bordt A.S., Bowden M.G., Sisson J.H., Woodruff P.G., Thornton D.J., Rousseau K., De la Garza M.M., Moghaddam S.J., Karmouty-Quintana H., Blackburn M.R., Drouin S.M., Davis C.W., Terrell K.A., Grubb B.R., O'Neal W.K., Flores S.C., Cota-Gomez A., Lozupone C.A., Donnelly J.M., Watson A.M., Hennessy C.E., Keith R.C., Yang I.V., Barthel L., Henson P.M., Janssen W.J., Schwartz D.A., Boucher R.C., Dickey B.F., Evans C.M. Muc5b is required for airway defence. Nature 2014, 505:412-416.
49. Molyneaux P.L., Cox M.J., Willis-Owen S.A., Mallia P., Russell K.E., Russell A.M., Murphy E., Johnston S.L., Schwartz D.A., Wells A.U., Cookson W.O., Maher T.M., Moffatt M.F. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014, 190:906-913.
50. Konstan M.W., Hilliard K.A., Norvell T.M., Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am. J. Respir. Crit. Care Med. 1994, 150:448-454.
51. Soler N., Ewig S., Torres A., Filella X., Gonzalez J., Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur. Respir. J. 1999, 14:1015-1022.
52. McFadden E.R., Pichurko B.M. Intraairway thermal profiles during exercise and hyperventilation in normal man. J. Clin. Invest. 1985, 76:1007-1010.
53. Papi A., Bellettato C.M., Braccioni F., Romagnoli M., Casolari P., Caramori G., Fabbri L.M., Johnston S.L. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006, 173:1114-1121.
54. Kanangat S., Meduri G.U., Tolley E.A., Patterson D.R., Meduri C.U., Pak C., Griffin J.P., Bronze M.S., Schaberg D.R. Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect. Immun. 1999, 67:2834-2840.
55. Kaza S.K., McClean S., Callaghan M. IL-8 released from human lung epithelial cells induced by cystic fibrosis pathogens Burkholderia cepacia complex affects the growth and intracellular survival of bacteria. Int. J. Med. Microbiol. 2011, 301:26-33.
56. Porat R., Clark B.D., Wolff S.M., Dinarello C.A. Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science 1991, 254:430-432.
57. Freestone P.P., Hirst R.A., Sandrini S.M., Sharaff F., Fry H., Hyman S., O'Callaghan C. Pseudomonas aeruginosa-catecholamine inotrope interactions: a contributory factor in the development of ventilator-associated pneumonia?. Chest 2012, 142:1200-1210.
58. Marks L.R., Davidson B.A., Knight P.R., Hakansson A.P. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. MBio 2013, 4.
59. Van de Graaf E.A., Out T.A., Roos C.M., Jansen H.M. Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids. Am. Rev. Respir. Dis. 1991, 143:362-368.
60. Sass A.M., Schmerk C., Agnoli K., Norville P.J., Eberl L., Valvano M.A., Mahenthiralingam E. The unexpected discovery of a novel low-oxygen-activated locus for the anoxic persistence of Burkholderia cenocepacia. ISME J. 2013, 7:1568-1581.
61. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214.
62. Goleva E., Jackson L.P., Harris J.K., Robertson C.E., Sutherland E.R., Hall C.F., Good J.T., Gelfand E.W., Martin R.J., Leung D.Y. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am. J. Respir. Crit. Care Med. 2013, 188:1193-1201.
63. Rogers G.B., van der Gast C.J., Cuthbertson L., Thomson S.K., Bruce K.D., Martin M.L., Serisier D.J. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013, 68:731-737.
64. Han M.K., Zhou Y., Murray S., Tayob N., Noth I., Lama V.N., Moore B.B., White E.S., Flaherty K.R., Huffnagle G.B., Martinez F.J. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Res. Med. 2014, 2(7):548-556.
65. Cox M.J., Allgaier M., Taylor B., Baek M.S., Huang Y.J., Daly R.A., Karaoz U., Andersen G.L., Brown R., Fujimura K.E., Wu B., Tran D., Koff J., Kleinhenz M.E., Nielson D., Brodie E.L., Lynch S.V. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 2010, 5:e11044.
66. Molyneaux P.L., Mallia P., Cox M.J., Footitt J., Willis-Owen S.A., Homola D., Trujillo-Torralbo M.B., Elkin S., Kon O.M., Cookson W.O., Moffatt M.F., Johnston S.L. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013, 188:1224-1231.
67. Zhao J., Murray S., Lipuma J.J. Modeling the impact of antibiotic exposure on human microbiota. Sci. Rep. 2014, 4:4345.
68. Bittar F., Richet H., Dubus J.C., Reynaud-Gaubert M., Stremler N., Sarles J., Raoult D., Rolain J.M. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008, 3:e2908.
69. Harris J.K., De Groote M.A., Sagel S.D., Zemanick E.T., Kapsner R., Penvari C., Kaess H., Deterding R.R., Accurso F.J., Pace N.R. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc. Natl. Acad. Sci. 2007, 104:20529-20533.
70. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G., Muhlebach M.S., Wolfgang M.C., Boucher R., Gilpin D.F., McDowell A., Elborn J.S. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008, 177:995-1001.
71. Worlitzsch D., Rintelen C., Böhm K., Wollschläger B., Merkel N., Borneff-Lipp M., Döring G. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin. Microbiol. Infect. 2009, 15:454-460.
72. Lozupone C., Cota-Gomez A., Palmer B.E., Linderman D.J., Charlson E.S., Sodergren E., Mitreva M., Abubucker S., Martin J., Yao G., Campbell T.B., Flores S.C., Ackerman G., Stombaugh J., Ursell L., Beck J.M., Curtis J.L., Young V.B., Lynch S.V., Huang L., Weinstock G.M., Knox K.S., Twigg H., Morris A., Ghedin E., Bushman F.D., Collman R.G., Knight R., Fontenot A.P. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am. J. Respir. Crit. Care Med. 2013, 187:1110-1117.
73. Flanagan J.L., Brodie E.L., Weng L., Lynch S.V., Garcia O., Brown R., Hugenholtz P., DeSantis T.Z., Andersen G.L., Wiener-Kronish J.P., Bristow J. Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J. Clin. Microbiol. 2007, 45:1954-1962.
74. Dickson R.P., Erb-Downward J.R., Prescott H.C., Martinez F.J., Curtis J.L., Lama V.N., Huffnagle G.B. Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid. J. Clin. Microbiol. 2014, 52:3605-3613.
75. Scales B.S., Dickson R.P., LiPuma J.J., Huffnagle G.B. Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans. Clin. Microbiol. Rev. 2014, 27:927-948.
76. Carmody L.A., Zhao J., Schloss P.D., Petrosino J.F., Murray S., Young V.B., Li J.Z., LiPuma J.J. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann. Am. Thorac. Soc. 2013, 10:179-187.
77. Millares L., Ferrari R., Gallego M., Garcia-Nunez M., Perez-Brocal V., Espasa M., Pomares X., Monton C., Moya A., Monso E. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33(7):1101-1111.
78. Price K.E., Hampton T.H., Gifford A.H., Dolben E.L., Hogan D.A., Morrison H.G., Sogin M.L., O'Toole G.A. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 2013, 1:27.
79. Stressmann F.A., Rogers G.B., Marsh P., Lilley A.K., Daniels T.W., Carroll M.P., Hoffman L.R., Jones G., Allen C.E., Patel N., Forbes B., Tuck A., Bruce K.D. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?. J. Cyst. Fibros. 2011, 10:357-365.
80. Iwai S., Huang D., Fong S., Jarlsberg L.G., Worodria W., Yoo S., Cattamanchi A., Davis J.L., Kaswabuli S., Segal M., Huang L., Lynch S.V. The lung microbiome of ugandan hiv-infected pneumonia patients is compositionally and functionally distinct from that of San Franciscan patients. PLoS One 2014, 9:e95726.
81. Angus D.C., van der Poll T. Severe sepsis and septic shock. N. Engl. J. Med. 2013, 369:2063.
82. Graham V., Lasserson T., Rowe B.H. Antibiotics for acute asthma. Cochrane Database Syst. Rev. 2001, CD002741.
83. Vollenweider D.J., Jarrett H., Steurer-Stey C.A., Garcia-Aymerich J., Puhan M.A. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012, 12:CD010257.
84. Simon R.H. Cystic fibrosis: antibiotic therapy for lung disease. UpToDate 2014, UpToDate, Waltham, MA. T.W. Post (Ed.).
85. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996, 22:387-394.
86. Hurley M.N., Ariff A.H., Bertenshaw C., Bhatt J., Smyth A.R. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 2012, 11:288-292.
87. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123:1495-1502.
88. Walker A.W., Sanderson J.D., Churcher C., Parkes G.C., Hudspith B.N., Rayment N., Brostoff J., Parkhill J., Dougan G., Petrovska L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011, 11:7.
89. Ordas I., Eckmann L., Talamini M., Baumgart D.C., Sandborn W.J. Ulcerative colitis. Lancet 2012, 380:1606-1619.
90. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J., Curtis J.L., Dransfield M.T., Han M.K., Lazarus S.C., Make B., Marchetti N., Martinez F.J., Madinger N.E., McEvoy C., Niewoehner D.E., Porsasz J., Price C.S., Reilly J., Scanlon P.D., Sciurba F.C., Scharf S.M., Washko G.R., Woodruff P.G., Anthonisen N.R. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011, 365:689-698.
91. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbell P.W. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
92. Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H., Milne D., Fergusson W., Tuffery C., Sexton P., Storey L., Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
93. Fellermann K., Ludwig D., Stahl M., David-Walek T., Stange E.F. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am. J. Gastroenterol. 1998, 93:1860-1866.
94. Hughes D.T., Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. Nat. Rev. Microbiol. 2008, 6:111-120.
95. Finlay B.B., McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124:767-782.
96. Casadevall A., Pirofski L.A. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 2003, 1:17-24.